Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

Abstract

Pegylated interferon alfa‐2a (PEG‐IFN) may induce sustained virological response (SVR) in 20% of hepatitis B e antigen (HBeAg)‐negative chronic hepatitis B (CHB) patients. In addition, loss of hepatitis B surface antigen (HBsAg) is achieved with a 10% yearly rate after treatment cessation in sustained responders. The aim of this study was to assess on‐treatment serum HBsAg kinetics to predict SVR in HBeAg‐negative patients treated with PEG‐IFN. Forty‐eight consecutive patients were treated with PEG‐IFN (180 μg/week) for 48 weeks. Serum hepatitis B virus (HBV) DNA (COBAS TaqMan) and HBsAg (Abbott Architect HBsAg QT assay) were assessed at baseline, during treatment (weeks 12, 24, and 48), and during follow‐up (weeks 72 and 96). SVR was defined as undetectable serum HBV DNA (10 IU/mL at weeks 12, 24, and 48, respectively. A decrease of 0.5 and 1 log₁₀ IU/mL in serum HBsAg levels at weeks 12 and 24 of therapy, respectively, had high predictive values of SVR (negative predictive value [NPV] 90%, positive predictive value [PPV] 89% for week 12; NPV 97%, PPV 92% for week 24). HBsAg loss was observed in three patients, all with SVR. Conclusion: Early serum HBsAg drop has high predictive values of SVR to PEG‐IFN in HBeAg‐negative CHB patients. Serum quantitative HBsAg may be a useful tool to optimize the management of PEG‐IFN therapy in these patients. (HEPATOLOGY 2009.)